Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic

Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic

The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease cause...

Full description

Bibliographic Details
Main Authors: G. Miranda-Zazueta, J.A. González-Regueiro, I. García-Juárez, C. Moctezuma-Velázquez, F.J. López-Díaz, B. Pérez-González, L.F. Uscanga-Domínguez, M. Peláez-Luna
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:Revista de Gastroenterología de México (English Edition)
Subjects:
COVID-19
Inmunosupresión
Coronavirus
Trasplante hepático
Hepatitis autoinmune
Online Access:http://www.sciencedirect.com/science/article/pii/S2255534X20300608

Internet

http://www.sciencedirect.com/science/article/pii/S2255534X20300608

Similar Items